Melt Pharmaceuticals' MELT-300 Shows Positive Phase 3 Results for Opioid-Free Cataract Surgery Sedation
Key Insights
MELT-300, a sublingual tablet combining midazolam and ketamine, demonstrated statistically superior procedural sedation compared to sublingual midazolam and placebo in cataract surgery (search) patients.
The proportion of patients requiring rescue sedation was nearly two-fold higher for sublingual midazolam compared to MELT-300, indicating a more effective and reliable sedation.
MELT-300 exhibited a favorable safety profile comparable to placebo, suggesting a well-tolerated alternative for procedural sedation during cataract surgery (search).
Melt Pharmaceuticals (search) has announced positive topline results from its Phase 3 clinical trial evaluating MELT-300, a novel sublingual tablet for procedural sedation during cataract surgery (search). The study demonstrated that MELT-300, a combination of midazolam (3mg) and ketamine (50mg), achieved statistically superior sedation compared to both sublingual midazolam and placebo.
The Phase 3 trial, conducted across 13 clinical sites in the United States, enrolled over 530 patients undergoing cataract surgery (search). Participants were randomized in a 4:1:1 ratio to receive MELT-300, sublingual midazolam, or sublingual placebo. The primary endpoint was the proportion of patients achieving successful procedural sedation.
The results indicated that MELT-300 was significantly more effective than both sublingual midazolam (P=0.009) and placebo (P<0.001) in providing successful procedural sedation. Furthermore, the need for rescue sedation was nearly two-fold higher in the sublingual midazolam group compared to the MELT-300 group (P=0.003), highlighting the enhanced efficacy and reliability of MELT-300.
Safety Profile
The safety profile of MELT-300 was generally comparable to placebo, suggesting that the combination of midazolam and ketamine, delivered sublingually, is well-tolerated in this patient population. This is a significant finding, as it supports the potential of MELT-300 to replace current IV-based cataract surgery (search) sedation protocols, which often involve the use of opioids.
Clinical Significance
"We are extremely excited with this robust topline data from our pivotal Phase 3 study," said Dr. Larry Dillaha, Chief Executive Officer of Melt. "These overwhelmingly positive results support our belief that MELT-300, if approved by the FDA, would be a safe and effective non-IV, non-opioid alternative to current IV-based cataract surgery (search) sedation protocols, which generally involve the administration of opioids."
With the number of cataract surgeries performed annually in the U.S. expected to exceed 5 million, the availability of a non-IV, non-opioid sedation option like MELT-300 could significantly improve patient experience and reduce the risks associated with traditional sedation methods. The sublingual administration, utilizing Catalent’s Zydis® delivery technology, allows for rapid absorption of the active ingredients, dissolving in as little as 3 seconds.
Future Implications
Melt Pharmaceuticals (search) intends to seek regulatory approval through the FDA’s 505(b)(2) regulatory pathway. The company believes that the Phase 3 data, along with previous Phase 2 results, position them well to elevate the procedural sedation standard of care for cataract surgery (search). Moreover, they plan to explore the potential expansion of MELT-300's use to other medical specialties, including dermatology, plastic surgery, dentistry, gastroenterology, and emergency care, potentially addressing over 100 million annual procedures.